Flexion Therapeutics
208 articles about Flexion Therapeutics
-
Flexion Therapeutics Reports Grants Under Nasdaq Listing Rule 5635(c)(4)
11/6/2020
Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced equity inducement grants to two new employees consisting of 3,315 restricted stock units. The Compensation Committee of the Board of Directors approved the grants with an effective date of November 2, 2020. The restricted stock units were granted as inducements material to the employees entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4). The r
-
Flexion Therapeutics to Present at the 29th Annual Credit Suisse Virtual Healthcare Conference
11/5/2020
Flexion Therapeutics, Inc. announced that Michael Clayman, M.D., President and Chief Executive Officer, will participate in an analyst-led fireside chat at the 29th Annual Credit Suisse Virtual Healthcare Conference.
-
As more and more gene therapies are approved, the elements that determine their success depend, increasingly, on the business decisions made early on.
-
Flexion Therapeutics Reports Third-Quarter 2020 Financial Results and Recent Business Highlights
11/4/2020
Companyreported ZILRETTA® (triamcinolone acetonide extended-release injectable suspension) net sales of $23.7 million in third quarter 2020
-
Flexion Therapeutics to Report Third-Quarter 2020 Financial Results on November 4, 2020
10/29/2020
Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that it will report its third-quarter 2020 financial results after the close of the U.S. financial markets on Wednesday, November 4, 2020. The company hosted a conference call on October 13, 2020, in conjunction with reporting preliminary third-quarter net sales. A replay of that call is available on Flexion’s corporate website: https://ir.flexiont h erapeutics.com/events-and-pres
-
Flexion Therapeutics Announces Preliminary Third-Quarter 2020 ZILRETTA® Net Sales of Approximately $23.6 MillionCompany to hold conference call today at 8:30 a.m. ET
10/13/2020
Flexion Therapeutics, Inc. announced preliminary ZILRETTA net sales of $23.6 million for the quarter ended September 30, 2020.
-
Flexion Therapeutics to Present at the 2020 Cell & Gene Virtual Meeting on the Mesa
10/8/2020
- Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced today that Adam Muzikant, Ph.D., Senior Vice President, Business Development, will present at the annual 2020 Cell & Gene Virtual Meeting on the Mesa. Dr. Muzikant will provide a review of FX201, an investigational, intra-articular, IL-1Ra gene therapy product candidate in clinical development for the treatment of osteoarthritis (OA). The Company is conducting an open-label, Phase 1 do
-
Flexion Therapeutics Announces Podium Presentation of FX301 Preclinical Data at Virtual ANESTHESIOLOGY 2020 Meeting
10/5/2020
Previously presented preclinical findings show FX301 provided greater sustained, post-operative analgesic effect with no significant impairment in motor function compared to liposomal bupivacaine and placebo BURLINGTON, Mass., Oct. 05, 2020 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced the podium presentation of preclinical efficacy and pharmacokinetic (PK) data for FX301, its locally administered peripheral nerve block candidate for control of post-operat
-
Flexion Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Oct 02, 2020
10/2/2020
Flexion Therapeutics, Inc. announced equity inducement grants to two new employees consisting of 3,315 restricted stock units.
-
Flexion Therapeutics to Present at the H.C. Wainwright Virtual Healthcare Conference
9/9/2020
Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced today that Michael Clayman, M.D., President and Chief Executive Officer, will participate in an analyst-led fireside chat at the H.C. Wainwright Virtual Healthcare Conference. The virtual fireside chat is scheduled to begin at 10:00 a.m. ET on Tuesday, September 15, 2020. To access the live webcast of the presentation, please visit the Flexion website at http://ir.flexiontherapeutics.c
-
Flexion Therapeutics Announces Treatment of First Patient in Second Cohort of FX201 Phase 1 Dose-Escalation Trial
9/8/2020
Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced the treatment of the first patient in the second cohort of the Phase 1 dose-escalation trial evaluating the safety and tolerability of FX201, an investigational, intra-articular, IL-1Ra gene therapy product candidate being developed for the treatment of osteoarthritis (OA).
-
Flexion Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Sep 04, 2020
9/4/2020
Flexion Therapeutics, Inc. announced equity inducement grants to three new employees consisting of 13,940 restricted stock units.
-
Flexion Therapeutics to Present at the Wells Fargo 2020 Virtual Healthcare Conference
9/3/2020
Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced today that Michael Clayman, M.D., President and Chief Executive Officer, will participate in an analyst-led fireside chat at the Wells Fargo 2020 Virtual Healthcare Conference. The virtual fireside chat is scheduled to begin at 10:40 a.m. ET on Wednesday, September 9, 2020. To access the live webcast of the presentation, please visit the Flexion website at http://ir.flexiontherapeutics.
-
Flexion Therapeutics Announces Appointment of Liz Kwo, MD, to its Board of Directors
8/19/2020
Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced the appointment of Elizabeth (Liz) Kwo, MD, Staff Vice President, Clinical Data Analytics at Anthem, to its Board of Directors. "We are delighted to welcome Liz to our Board of Directors as her broad and deep background uniquely complements our existing skills and experiences,” said Michael Clayman, MD, President and Chief Executive Officer of Flexion Therapeutics. “We are confident
-
Flexion Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Aug 07, 2020
8/7/2020
Flexion Therapeutics, Inc. announced equity inducement grants to two new employees consisting of 25,315 restricted stock units.
-
Flexion Therapeutics Reports Second-Quarter 2020 Financial Results and Recent Business Highlights
8/5/2020
Company reported ZILRETTA® (triamcinolone acetonide extended-release injectable suspension) net sales of $15.5 million in second quarter 2020
-
Flexion Therapeutics to Report Second-Quarter 2020 Financial Results on August 5, 2020
7/30/2020
Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that it will report its second-quarter 2020 financial results and recent business highlights after the close of the U.S. financial markets on Wednesday, August 5, 2020.
-
Flexion Therapeutics Announces Preliminary Second-Quarter 2020 ZILRETTA® Net Sales
7/14/2020
Company reported ZILRETTA (triamcinolone acetonide extended-release injectable suspension) preliminary net sales of $15.4 million in the second quarter
-
Flexion Therapeutics to Present at the BMO 2020 Prescriptions for Success Healthcare Conference
6/16/2020
Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced today that Michael Clayman, M.D., President and Chief Executive Officer, will participate in an analyst-led fireside chat at the BMO 2020 Prescriptions for Success Healthcare Conference.
-
Flexion Therapeutics Announces Pricing of Public Offering of Common Stock - May 21, 2020
5/21/2020
Flexion Therapeutics, Inc. announced the pricing of an underwritten public offering of 9,230,770 shares of its common stock at a price to the public of $9.75 per share.